Literature DB >> 17033781

[Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma].

A Schäffler1.   

Abstract

Evidence based drug therapy is currently available for the treatment of prolactinomas and growth hormone secreting adenomas (acromegaly). Dopamine agonists such as bromocriptine, quinagolide or cabergoline represent the standard therapy for the treatment of micro- and macro-prolaktinomas. In pregnancy, more differentiated, individual and patient-adapted therapeutic procedures have to be considered. Transsphenoidal adenomectomy is the treatment of choice for patients suffering from acromegaly. If biochemical cure (defined by normalized IGF-1 serum levels or by a GH nadir <1 microg/l during a 3-h oral glucose tolerance test) cannot be achieved, somatostatin analogues such as octreotide and lanreotide are effective. In some cases, dopamine agonists can be added. In therapy-resistant cases, growth hormone receptor antagonists can be used.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033781     DOI: 10.1007/s00108-006-1727-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  38 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 2.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

Authors:  John S Bevan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

Authors:  A J van der Lely ; A Muller; J A Janssen; R J Davis; K A Zib; J A Scarlett; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Oral contraceptives and pituitary adenomas.

Authors:  S J Wingrave; C R Kay; M P Vessey
Journal:  Br Med J       Date:  1980-03-08

5.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

6.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Authors:  Shlomo Melmed; Richard Sternberg; David Cook; Anne Klibanski; Philippe Chanson; Vivien Bonert; Mary Lee Vance; David Rhew; David Kleinberg; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2005-04-12       Impact factor: 5.958

7.  Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.

Authors:  M Bronstein; N Musolino; R Jallad; J M Cendros; J Ramis; R Obach; A Leselbaum; F Catus
Journal:  Clin Endocrinol (Oxf)       Date:  2005-11       Impact factor: 3.478

8.  Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.

Authors:  Annamaria Colao; Giovanni Vitale; Paolo Cappabianca; Francesco Briganti; Antonio Ciccarelli; Michele De Rosa; Stefano Zarrilli; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

9.  Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.

Authors:  A Colao; A Di Sarno; M L Landi; S Cirillo; F Sarnacchiaro; G Facciolli; R Pivonello; M Cataldi; B Merola; L Annunziato; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

10.  One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.

Authors:  Ph Caron; M Bex; D R Cullen; U Feldt-Rasmussen; A M Pico Alfonso; S Pynka; K Racz; J Schopohl; A Tabarin; M J Valimaki
Journal:  Clin Endocrinol (Oxf)       Date:  2004-06       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.